CY1124913T1 - Ν-υποκατεστημενα παραγωγα ινδολης ως διαμορφωτες υποδοχεα pge2 - Google Patents

Ν-υποκατεστημενα παραγωγα ινδολης ως διαμορφωτες υποδοχεα pge2

Info

Publication number
CY1124913T1
CY1124913T1 CY20211101035T CY211101035T CY1124913T1 CY 1124913 T1 CY1124913 T1 CY 1124913T1 CY 20211101035 T CY20211101035 T CY 20211101035T CY 211101035 T CY211101035 T CY 211101035T CY 1124913 T1 CY1124913 T1 CY 1124913T1
Authority
CY
Cyprus
Prior art keywords
receptor modulators
indole derivatives
substituted indole
pge2 receptor
chemical formula
Prior art date
Application number
CY20211101035T
Other languages
English (en)
Inventor
Heinz Fretz
Isabelle Lyothier
Sylvia Richard-Bildstein
Thierry Sifferlen
Lorenza WYDER PETERS
Davide Pozzi
Olivier Corminboeuf
Julien Pothier
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of CY1124913T1 publication Critical patent/CY1124913T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

Η παρούσα εφεύρεση σχετίζεται με παράγωγα του χημικού τύπου (Ι), όπου τα (R1)n, R2, R3, R4a, R4b, R5a, R5b και Ar1 είναι όπως περιγράφηκαν στην περιγραφή, με την παρασκευή τους, τα φαρμακευτικά αποδεκτά άλατα τους, καθώς και με τη χρήση τους ως φαρμακευτικές ουσίες, σε φαρμακευτικές συνθέσεις που περιέχουν μια ή περισσότερες ενώσεις του χημικού τύπου (Ι), και κυρίως με τη χρήση τους ως διαμορφωτές των υποδοχέων ΕΡ2 και/ ή ΕΡ4 της προσταγλανδίνης 2.
CY20211101035T 2015-11-20 2021-11-30 Ν-υποκατεστημενα παραγωγα ινδολης ως διαμορφωτες υποδοχεα pge2 CY1124913T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2015077269 2015-11-20
PCT/EP2016/078028 WO2017085198A1 (en) 2015-11-20 2016-11-17 N-substituted indole derivatives as pge2 receptor modulators

Publications (1)

Publication Number Publication Date
CY1124913T1 true CY1124913T1 (el) 2023-01-05

Family

ID=57326428

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211101035T CY1124913T1 (el) 2015-11-20 2021-11-30 Ν-υποκατεστημενα παραγωγα ινδολης ως διαμορφωτες υποδοχεα pge2

Country Status (33)

Country Link
US (2) US11241431B2 (el)
EP (2) EP3928836A1 (el)
JP (2) JP2018534328A (el)
KR (1) KR102352022B1 (el)
CN (1) CN108349949B (el)
AU (1) AU2016358242B2 (el)
BR (1) BR112018010291B1 (el)
CA (1) CA3002610C (el)
CL (1) CL2018001325A1 (el)
CO (1) CO2018005715A2 (el)
CR (1) CR20180323A (el)
CY (1) CY1124913T1 (el)
DK (1) DK3377483T3 (el)
EA (1) EA037953B1 (el)
ES (1) ES2897954T3 (el)
HR (1) HRP20211678T1 (el)
HU (1) HUE056679T2 (el)
IL (1) IL259424B (el)
LT (1) LT3377483T (el)
MA (2) MA43251B1 (el)
MX (1) MX2018005268A (el)
MY (1) MY195888A (el)
PE (1) PE20181304A1 (el)
PH (1) PH12018501077B1 (el)
PL (1) PL3377483T3 (el)
PT (1) PT3377483T (el)
RS (1) RS62598B1 (el)
SA (1) SA518391588B1 (el)
SG (1) SG11201803627XA (el)
SI (1) SI3377483T1 (el)
TW (2) TWI754397B (el)
UA (1) UA123441C2 (el)
WO (1) WO2017085198A1 (el)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20180323A (es) * 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
TW201900179A (zh) 2017-05-18 2019-01-01 瑞士商愛杜西亞製藥有限公司 作為pge2受體調節劑之苯并呋喃及苯并噻吩衍生物
TW201900178A (zh) 2017-05-18 2019-01-01 瑞士商愛杜西亞製藥有限公司 作為pge2受體調節劑之嘧啶衍生物
CA3063788A1 (en) 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives
MA49126B1 (fr) 2017-05-18 2021-10-29 Idorsia Pharmaceuticals Ltd Dérivés de phényle utilisés en tant que modulateurs des récepteurs des pge2
CN109678780A (zh) * 2017-10-19 2019-04-26 中国石油化工股份有限公司 一种制备3-烷基吲哚衍生物的方法
AU2018368790A1 (en) 2017-11-20 2020-06-25 Ichan School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
AU2019205944A1 (en) 2018-01-05 2020-07-09 Icahn School Of Medicine At Mount Sinai Method of increasing proliferation of pancreatic beta cells, treatment method, and composition
WO2019183245A1 (en) 2018-03-20 2019-09-26 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
US20220064146A1 (en) * 2018-12-31 2022-03-03 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
EP3693359A1 (en) 2019-02-08 2020-08-12 Medibiofarma, S.L. New n-benzyl-2-phenoxybenzamide derivatives as prostaglandin e2 (pge2) receptors modulators
WO2021060281A1 (ja) * 2019-09-24 2021-04-01 Ａｇｃ株式会社 プロスタグランジンｅ２レセプターｅｐ２／ｅｐ４デュアルアンタゴニスト
KR20230107228A (ko) 2020-11-13 2023-07-14 오노 야꾸힝 고교 가부시키가이샤 Ep4 길항약과 면역 체크포인트 저해 물질의 병용에 의한 암 치료

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948786A (en) 1996-04-12 1999-09-07 Sumitomo Pharmaceuticals Company, Limited Piperidinylpyrimidine derivatives
AU3445100A (en) 2000-03-24 2001-10-08 Pharmagene Lab Ltd Use of prostanoid ep4 receptor antagonists for the treatment of headache and assays for such antagonists
HN2001000224A (es) 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
GB0031295D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Naphthalene derivatives
GB0031302D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Napthalene derivatives
GB0103269D0 (en) 2001-02-09 2001-03-28 Glaxo Group Ltd Napthalene derivatives
BR0309305A (pt) 2002-04-12 2005-02-15 Pfizer Compostos de imidazol como agentes antiinflamatórios e analgésicos
WO2003087061A1 (en) 2002-04-12 2003-10-23 Pfizer Japan Inc. Pyrazole compounds as anti-inflammatory and analgesic agents
BR0311247A (pt) 2002-05-23 2005-03-15 Theratechnologies Inc Peptìdeos antagonistas do receptor subtipo ep4 da prostaglandina e2
WO2004067524A1 (en) 2003-01-29 2004-08-12 Pharmagene Laboratories Limited Ep4 receptor antagonists
EP1661896A4 (en) 2003-08-26 2008-07-16 Teijin Pharma Ltd PYRROLOPYRIMIDINETHIONDERIVAT
BRPI0414130B8 (pt) 2003-09-03 2021-05-25 Askat Inc compostos de fenilamida ou piridilamida, seu uso e composições farmacêuticas que os compreendem.
EP1678147B1 (en) 2003-09-15 2012-08-08 Lead Discovery Center GmbH Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
US7326732B2 (en) * 2004-02-12 2008-02-05 Pharmagene Laboratories Limited EP2 receptor agonists
CA2565813C (en) 2004-05-04 2010-10-26 Pfizer Inc. Substituted methyl aryl or heteroaryl amide compounds
JP4054369B2 (ja) 2004-05-04 2008-02-27 ファイザー株式会社 オルト置換アリールまたはヘテロアリールアミド化合物
HN2005000795A (es) 2004-10-15 2010-08-19 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
EP1885722B1 (en) 2005-05-19 2011-11-16 Merck Canada Inc. Quinoline derivatives as ep4 antagonists
WO2006128129A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
AR060403A1 (es) 2006-04-12 2008-06-11 Sanofi Aventis Compuestos de amino- pirimidina 2,6- sustituidos -4- monosustituidos como antagonistas del receptor de prostaglandina d2
WO2007121578A1 (en) 2006-04-24 2007-11-01 Merck Frosst Canada Ltd. Indole amide derivatives as ep4 receptor antagonists
AU2007260529B2 (en) 2006-06-12 2012-04-19 Merck Canada Inc. Indoline amide derivatives as EP4 receptor ligands
US20080280891A1 (en) 2006-06-27 2008-11-13 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
WO2008008059A1 (en) 2006-07-12 2008-01-17 Locus Pharmaceuticals, Inc. Anti-cancer agents ans uses thereof
PT2044056E (pt) * 2006-07-14 2012-12-05 Novartis Ag Derivados de pirimidina como inibidores de alk-5
JP5259592B2 (ja) 2006-08-11 2013-08-07 メルク カナダ インコーポレイテッド Ｅｐ４受容体リガンドとしてのチオフェンカルボキサミド誘導体
WO2008039882A1 (en) 2006-09-30 2008-04-03 Sanofi-Aventis U.S. Llc A combination of niacin and a prostaglandin d2 receptor antagonist
AU2008221194B2 (en) 2007-02-26 2013-06-27 Merck Canada Inc. Indole and indoline cyclopropyl amide derivatives as EP4 receptor antagonists
CN101641325A (zh) 2007-03-26 2010-02-03 安斯泰来制药株式会社 鸟氨酸衍生物
WO2008116304A1 (en) 2007-03-26 2008-10-02 Merck Frosst Canada Ltd. Naphthalene and quinoline sulfonylurea derivatives as ep4 receptor antagonists
EP2014657A1 (de) 2007-06-21 2009-01-14 Bayer Schering Pharma Aktiengesellschaft Diaminopyrimidine als Modulatoren des EP2-Rezeptors
EP2460787A1 (en) 2007-07-03 2012-06-06 Astellas Pharma Inc. Amide compounds and their use as PGE2 antagonists.
NZ584454A (en) 2007-10-12 2011-09-30 Ingenium Pharmaceuticals Gmbh N-[6-phenyl-pyrimidin-4-yl]-amides and urea derivatives as inhibitors of protein kinases
CA2714743C (en) 2008-02-19 2017-01-17 Janssen Pharmaceutica N.V. Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase
SI2565191T1 (sl) 2008-05-14 2014-12-31 Astellas Pharma Inc. Derivati 4-(indol-7-ilkarbonilaminometil)cikloheksan karboksilne kisline kot EP4 receptorski antagonisti, uporabni za zdravljenje kronične ledvične odpovedi ali diabetične nefropatije
US20130225528A1 (en) 2008-05-21 2013-08-29 Ariad Pharmaceuticals, Inc. Phosphorus Derivatives as Kinase Inhibitors
CA2733247C (en) 2008-08-14 2018-04-03 Beta Pharma Canada Inc. Heterocyclic amide derivatives as ep4 receptor antagonists
WO2010032123A1 (en) 2008-09-19 2010-03-25 Biotechnology Research Corporation Limited Triterpenoid compounds and methods of use thereof
US8685999B2 (en) 2008-09-25 2014-04-01 Merck Sharp & Dohme Corp. Beta carboline sulphonylurea derivatives as EP4 receptor antagonists
US8906914B2 (en) 2009-08-18 2014-12-09 Janssen Pharmaceutica Nv Ethylene diamine modulators of fatty acid hydrolase
AU2010321905A1 (en) 2009-11-23 2012-05-24 Lexicon Pharmaceuticals, Inc. Methods and assays for the treatment of irritable bowel syndrome
CA2798578C (en) 2010-05-21 2015-12-29 Chemilia Ab Novel pyrimidine derivatives
MX2013003162A (es) 2010-09-21 2013-05-06 Eisai R&D Man Co Ltd Composicion farmaceutica.
AU2011309028B2 (en) 2010-09-29 2016-03-17 Nb Health Laboratory Co. Ltd. Antibody against human prostaglandin E2 receptor EP4
WO2012066065A1 (en) 2010-11-17 2012-05-24 Novartis Ag Phenyl-heteroaryl amine compounds and their uses
CA2816679A1 (en) 2010-11-17 2012-05-24 Novartis Ag 3-(aminoaryl)-pyridine compounds
ES2545110T3 (es) 2010-12-10 2015-09-08 Rottapharm Biotech S.R.L. Derivados de piridinamida como antagonistas del receptor EP4
WO2012103071A2 (en) 2011-01-25 2012-08-02 Eisai R&D Management Co., Ltd. Compounds and compositions
RU2013147417A (ru) 2011-03-24 2015-04-27 Кемилиа Аб Новые производные пиримидина
EP2702043A1 (en) 2011-04-29 2014-03-05 Exelixis, Inc. Inhibitors of inducible form of 6-phosphofructose-2-kinase
US9518044B2 (en) 2011-06-20 2016-12-13 Emory University Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto
ES2559513T3 (es) 2011-07-04 2016-02-12 Rottapharm Biotech S.R.L. Derivados de amina cíclica como antagonistas del receptor EP4
EP2554662A1 (en) 2011-08-05 2013-02-06 M Maria Pia Cosma Methods of treatment of retinal degeneration diseases
US20150004175A1 (en) 2011-12-13 2015-01-01 Yale University Compositions and Methods for Reducing CTL Exhaustion
EP2841428B1 (en) 2012-04-24 2018-08-22 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors
JO3296B1 (ar) 2012-06-29 2018-09-16 Lilly Co Eli مركبات فينوكسي إيثيل بيبريدين
TWI572597B (zh) 2012-06-29 2017-03-01 美國禮來大藥廠 二甲基－苯甲酸化合物
EP2711364A1 (en) 2012-09-21 2014-03-26 Chemilia AB 4-(Indolyl or benzimidazolyl)amino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer
CA2888338C (en) 2012-11-27 2021-07-20 Thomas Helledays Stiftelse For Medicinsk Forskning Mth1 inhibitors for treatment of cancer
UA115576C2 (uk) 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
EP2765128A1 (en) 2013-02-07 2014-08-13 Almirall, S.A. Substituted benzamides with activity towards EP4 receptors
TW201443004A (zh) 2013-02-15 2014-11-16 Lilly Co Eli 苯氧基乙氧基化合物
TWI636046B (zh) 2013-05-17 2018-09-21 美國禮來大藥廠 苯氧基乙基二氫－１ｈ－異喹啉化合物
AU2014279113B2 (en) 2013-06-12 2018-04-12 Kaken Pharmaceutical Co., Ltd. 4-alkynyl imidazole derivative and medicine comprising same as active ingredient
CN105705489B (zh) 2013-09-04 2019-04-26 百时美施贵宝公司 用作免疫调节剂的化合物
AU2014316682B2 (en) 2013-09-06 2018-11-22 Aurigene Discovery Technologies Limited 1,2,4-oxadiazole derivatives as immunomodulators
WO2015044900A1 (en) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Therapeutic immunomodulating compounds
BR112016008423B1 (pt) 2013-10-17 2022-02-22 Vertex Pharmaceuticals Incorporated Composto, composição farmacêutica compreendendo o mesmo e seu uso
RU2675270C2 (ru) 2013-10-17 2018-12-18 Вертекс Фармасьютикалз Инкорпорейтед Сокристаллы и содержащие их фармацевтические композиции
EA028675B1 (ru) 2013-12-17 2017-12-29 Эли Лилли Энд Компани Соединения диметилбензойной кислоты
CN105793242B (zh) 2013-12-17 2018-02-16 伊莱利利公司 苯氧基乙基环状胺衍生物及其作为ep4受体调节剂的活性
TW201607943A (zh) 2013-12-19 2016-03-01 拜耳製藥公司 作為ｅｐ４配體之新穎苯并咪唑衍生物
TW201623277A (zh) 2014-03-26 2016-07-01 安斯泰來製藥股份有限公司 醯胺化合物
WO2015167825A1 (en) 2014-04-29 2015-11-05 Emory University Prostaglandin receptor ep2 antagonists, derivatives, compositions, and uses related thereto
CN110354266A (zh) 2014-05-23 2019-10-22 卫材 R&D 管理有限公司 用于治疗癌症的组合疗法
EP3151833A4 (en) 2014-06-04 2018-01-10 Thomas Helledays Stiftelse För Medicinsk Forskning Mth1 inhibitors for treatment of inflammatory and autoimmune conditions
WO2016021742A1 (en) 2014-08-07 2016-02-11 Takeda Pharmaceutical Company Limited Heterocyclic compounds as ep4 receptor antagonists
NZ733575A (en) 2015-01-09 2022-10-28 Ono Pharmaceutical Co Tricyclic spiro compound
WO2017014323A1 (en) 2015-07-23 2017-01-26 Takeda Pharmaceutical Company Limited 1-substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as ep4 receptor antagonists
CN108473497B (zh) 2015-10-16 2021-09-10 卫材R&D 管理有限公司 Ep4拮抗剂
CR20180323A (es) * 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
JP7033583B2 (ja) 2016-07-13 2022-03-10 バーテックス ファーマシューティカルズ インコーポレイテッド ゲノム編集効率を高めるための方法、組成物及びキット
MA49126B1 (fr) 2017-05-18 2021-10-29 Idorsia Pharmaceuticals Ltd Dérivés de phényle utilisés en tant que modulateurs des récepteurs des pge2
TW201900178A (zh) 2017-05-18 2019-01-01 瑞士商愛杜西亞製藥有限公司 作為pge2受體調節劑之嘧啶衍生物
TW201900179A (zh) 2017-05-18 2019-01-01 瑞士商愛杜西亞製藥有限公司 作為pge2受體調節劑之苯并呋喃及苯并噻吩衍生物
UA124748C2 (uk) 2017-05-18 2021-11-10 Ідорсія Фармасьютікалз Лтд N-заміщені індольні похідні
CA3063788A1 (en) 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives

Also Published As

Publication number Publication date
HUE056679T2 (hu) 2022-02-28
ES2897954T3 (es) 2022-03-03
MA43251A (fr) 2021-04-28
CR20180323A (es) 2018-08-06
BR112018010291A2 (pt) 2018-11-06
SI3377483T1 (sl) 2022-01-31
US20200289507A1 (en) 2020-09-17
JP2018534328A (ja) 2018-11-22
JP7228618B2 (ja) 2023-02-24
TW202120497A (zh) 2021-06-01
PL3377483T3 (pl) 2022-01-31
TWI754397B (zh) 2022-02-01
BR112018010291B1 (pt) 2023-12-26
SA518391588B1 (ar) 2021-03-17
CA3002610A1 (en) 2017-05-26
EA201891179A1 (ru) 2018-11-30
MA43251B1 (fr) 2021-11-30
IL259424B (en) 2020-11-30
US11241431B2 (en) 2022-02-08
KR20180081810A (ko) 2018-07-17
CN108349949B (zh) 2020-11-17
EA037953B1 (ru) 2021-06-11
PH12018501077A1 (en) 2019-01-28
EP3377483A1 (en) 2018-09-26
PE20181304A1 (es) 2018-08-09
TW201726661A (zh) 2017-08-01
CL2018001325A1 (es) 2018-08-10
AU2016358242A1 (en) 2018-07-05
CA3002610C (en) 2022-03-15
PT3377483T (pt) 2021-11-22
HRP20211678T1 (hr) 2022-03-04
KR102352022B1 (ko) 2022-01-14
CO2018005715A2 (es) 2018-07-10
EP3928836A1 (en) 2021-12-29
WO2017085198A1 (en) 2017-05-26
MY195888A (en) 2023-02-27
EP3377483B9 (en) 2022-08-03
IL259424A (en) 2018-07-31
DK3377483T3 (da) 2021-12-06
MX2018005268A (es) 2018-11-29
PH12018501077B1 (en) 2019-01-28
EP3377483B1 (en) 2021-09-01
LT3377483T (lt) 2021-11-10
UA123441C2 (uk) 2021-04-07
RS62598B1 (sr) 2021-12-31
SG11201803627XA (en) 2018-06-28
JP2021107417A (ja) 2021-07-29
MA55046A (fr) 2021-12-29
US20220175775A1 (en) 2022-06-09
TWI719078B (zh) 2021-02-21
AU2016358242B2 (en) 2021-03-11
CN108349949A (zh) 2018-07-31

Similar Documents

Publication Publication Date Title
CY1124913T1 (el) Ν-υποκατεστημενα παραγωγα ινδολης ως διαμορφωτες υποδοχεα pge2
CY1124726T1 (el) Παραγωγα κιναζολινης που χρησιμοποιουνται για την αντιμετωπιση του hiv
ECSP20070854A (es) Compuestos heteroaril tetracíclicos
CY1121418T1 (el) Παρεμποδιστες ιου ηπατιτιδας c
CY1124528T1 (el) Ν-υποκατεστημενα παραγωγα ινδολης
ECSP19028657A (es) Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f] isoquinolina útiles en el tratamiento del cáncer
CY1118735T1 (el) Παραγωγα βενζιμιδαζολο-προλινης
CY1124799T1 (el) Παραγωγα πυριμιδινης ως ρυθμιστες υποδοχεα pge2
CY1124608T1 (el) Παραγωγα φαινυλιου ως ρυθμιστες υποδοχεα pge2
CY1122731T1 (el) Διαμορφωτες υποδοχεα οιστρογονων
UY35275A (es) Derivados de aminopirazina
CY1125016T1 (el) Διαμορφωτες υποδοχεα πιπεριδινης cxcr7
EA201791600A1 (ru) Производные гидроксиалкилпиперазина в качестве модуляторов cxcr3 рецептора
CY1121650T1 (el) Αναστολεις συνθασης αλδοστερονης
CY1122321T1 (el) Παραγωγα φθοροϊνδολιου ως θετικοι αλλοστερικοι διαμορφωτες του μουσκαρινικου υποδοχεα μ1
EA201501163A1 (ru) Модуляторы рецептора cxcr7
CY1123185T1 (el) Παραγωγα ινδολιου
CO2019004143A2 (es) Compuestos azaheterocíclicos fusionados y su uso como moduladores de los receptores ampa
ECSP18056196A (es) Derivados de indano
EA201891027A1 (ru) Фармацевтическая композиция, содержащая производные индола, способ ее получения и применение
TH158992A (th) อนุพันธ์เบนซิมิดาโซล-โปรลีน